Travmatologiâ i Ortopediâ Rossii (Dec 2024)

Use of multipotent mesenchymal stromal cells as part of bone marrow concentrate in the complex treatment of aseptic necrosis of the femoral head: a systematic review

  • Alina R. Zakirova,
  • Alexander N. Torgashin,
  • Svetlana S. Rodionova

DOI
https://doi.org/10.17816/2311-2905-17489
Journal volume & issue
Vol. 30, no. 4
pp. 146 – 156

Abstract

Read online

Background. Avascular necrosis of the femoral head (ANFH) is a disabling disease that often leads to hip replacement. Due to the increasing incidence among the young population, various methods of organ-preserving treatment aimed at slowing down the progression of ANFH and preserving the functions of the hip joint have been proposed. Today, there is a lot of controversy and disagreement over the procedure of introducing bone marrow-derived multipotent mesenchymal stromal cells (MMSCs) into the site of osteonecrosis. The aim of the study — a systematic analysis of the accumulated literature data on the effectiveness, safety, advantages and disadvantages of treating patients with aseptic necrosis of the femoral head by the tunneling method using bone marrow-derived MMSCs, as well as their impact on reducing the risk of disease progression and long-term treatment results. Methods. A 10-year literature search (2013-2023) was performed in the PubMed, Scopus and eLIBRARY databases. According to our inclusion criteria, the review included 8 high-quality studies that examined the use of MMSCs as part of bone marrow concentrate for the treatment of ANFH. Results. The surgical outcomes of 368 patients (548 hips) from 8 studies were analyzed. The mean follow-up period was from 24 to 360 months. In most cases, functional indicators improved. In the main group, where mesenchymal stromal cells were used, X-ray progression to the next stage occurred in 31.25% of cases and the need for endoprosthetics was 30.6%; in the comparison group, the progression occurred in 68.75% of cases and the need for endoprosthetics was 69.4 %. Conclusion. The use of multipotent mesenchymal stromal cells in the complex treatment of ANFH in the early (ARCO I, II, IIIA) stages of the disease can improve the hip joint function, slow down the progression of the disease and reduce the need for endoprosthetics.

Keywords